Evidence of co-infections during Delta and Omicron SARS-CoV-2 variants co-circulation through prospective screening and sequencing.

Delta and Omicron VOC Recombination SARS-CoV-2 co-infection Single nucleotide polymorphism screening Whole genome sequencing

Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 14 03 2022
revised: 17 06 2022
accepted: 28 06 2022
pubmed: 7 7 2022
medline: 27 10 2022
entrez: 6 7 2022
Statut: ppublish

Résumé

To describe Delta/Omicron SARS-CoV-2 variants co-infection detection and confirmation during the fifth wave of COVID-19 pandemics in France in 7 immunocompetent and epidemiologically unrelated patients. Since December 2021, the surveillance of Delta/Omicron SARS-CoV-2 variants of concern (VOC) circulation was performed through prospective screening of positive-samples using single nucleotide polymorphism (SNP) PCR assays targeting SARS-CoV-2 S-gene mutations K417N (Omicron specific) and L452R (Delta specific). Samples showing unexpected mutational profiles were further submitted to whole genome sequencing (WGS) using three different primer sets. Between weeks 49-2021 and 02-2022, SARS-CoV-2 genome was detected in 3831 respiratory samples, of which 3237 (84.5%) were screened for VOC specific SNPs. Unexpected mutation profiles suggesting a dual Delta/Omicron population were observed in 7 nasopharyngeal samples (0.2%). These co-infections were confirmed by WGS. For 2 patients, the sequence analyses of longitudinal samples collected 7 to 11 days apart showed that Delta or Omicron can outcompete the other variant during dual infection. Additionally, for one of these samples, a recombination event between Delta and Omicron was detected. This work demonstrates that SARS-CoV-2 Delta/Omicron co-infections are not rare in high virus co-circulation periods. Moreover, co-infections can further lead to genetic recombination which may generate new chimeric variants with unpredictable epidemic or pathogenic properties that could represent a serious health threat.

Identifiants

pubmed: 35792280
pii: S1198-743X(22)00345-7
doi: 10.1016/j.cmi.2022.06.030
pmc: PMC9250411
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1503.e5-1503.e8

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Infect Genet Evol. 2015 Mar;30:296-307
pubmed: 25541518
Nat Commun. 2022 Oct 23;13(1):6316
pubmed: 36274062
BMC Infect Dis. 2021 Sep 16;21(1):959
pubmed: 34530778
Microorganisms. 2021 Feb 02;9(2):
pubmed: 33540596
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Nat Commun. 2022 May 18;13(1):2745
pubmed: 35585202
Clin Microbiol Infect. 2022 Jan;28(1):139.e5-139.e8
pubmed: 34537363
Cell. 2021 Sep 30;184(20):5179-5188.e8
pubmed: 34499854
Front Public Health. 2022 Jan 04;9:818401
pubmed: 35059385
Front Public Health. 2022 Feb 22;10:849978
pubmed: 35273945

Auteurs

Patricia Combes (P)

CHU Clermont-Ferrand, pôle BMAP, F-63003 Clermont-Ferrand, France.

Maxime Bisseux (M)

CHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France.

Antonin Bal (A)

GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004 Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.

Pierre Marin (P)

CHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France.

Justine Latour (J)

CHU de Toulouse, Virology Laboratory, F-31300 Toulouse, France.

Christine Archimbaud (C)

CHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France.

Amélie Brebion (A)

CHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France.

Hélène Chabrolles (H)

CHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France.

Christel Regagnon (C)

CHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France.

Jérémy Lafolie (J)

CH Vichy, Laboratory Department, F-03000 Vichy, France.

Gregory Destras (G)

GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004 Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.

Bruno Simon (B)

GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004 Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.

Jacques Izopet (J)

CHU de Toulouse, Virology Laboratory, F-31300 Toulouse, France; INFINITY, INSERM UMR291-CNRS UMR5051-Toulouse University, F-31300 Toulouse, France; Université Toulouse III Paul Sabatier, F-31300 Toulouse, France.
GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004 Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.

Cécile Henquell (C)

CHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France.

Audrey Mirand (A)

CHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France. Electronic address: amirand@chu-clermontferrand.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH